License Purchase Obligation (Details Textual) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Feb. 28, 2019	Jul. 31, 2017	Dec. 31, 2019	Dec. 31, 2018
License Purchase Obligation (Textual)
Reduced annual royalties description	In February 2019, the Company and Resdevco agreed that the Company shall pay Resdevco minimum yearly payments of $150,000 per year through 2021, and then annual payments of $475,000 per year, and shall pay Resdevco $650,000 within two years after receipt of FDA approval for eye drops utilizing the licensed technology.
License Agreement [Member]
License Purchase Obligation (Textual)
Licensing fees and royalties		$ 150	$ 150	$ 150
Reduced annual royalties description		Wize Israel and Resdevco amended the License Agreement pursuant to which the annual royalties amount of $475 were reduced to $150 for 2018 and 2019. In addition, If Wize Israel would have obtained an FDA marketing license during 2019, the Company was also required to pay Resdevco the remainder of the payment of 2019, however, such approval was not achieved in 2019. Consequently, during the third quarter of 2017 the Company has recognized an amount of $150 as an additional liability with respect to the 2018 minimum commitment, which was paid during the third quarter of 2018. In addition, during the third quarter of 2018 the Company has recognized an amount of $150 as a liability in respect to the 2019 minimum commitment.